Table 3.

Characteristics of Brincidofovir tested in preclinical studies.

Ref.	Samples	Intervention	Comparison	Method
Hutson, et al. [23]	Black-tailed prairie dogs, Cynomys ludovicianus Plasma conc. Of BCV study; n = 16, 8 M & 8 F, aged 2–4 years & weighed 913–1230 g Efficacy study; n = 28 F, aged—4 years	(1)Plasma conc. Of BCV study; 3-doses oral regimen; 20 mg/kg & 5 mg/kg (2)Efficacy study; 3-doses oral regimen; 20 mg/kg (1st dose) & 5 mg/kg (2nd & 3rd dose)	Vehicle	Plasma concentration of BCV following single and repeat oral administration	Determining the efficacy of BCV in animals challenged with MPXV
				Animals were distributed & received 3-doses oral regimen; (1)20 mg/kg (n = 8) (2)5 mg/kg (n = 8)	Animals distributed into 4 groups; (1)Positive control—Vehicle-treated (n = 7) (2)Treated with BCV on day 1 pre-infection (n = 7) (3)Treated with BCV on day 0 (n = 7) (4)Treated with BCV on day 1 post-infection (n = 7) West African MPXV strain was inoculated to animals.